SCHEMBL6491504

SCHEMBL6491504

Cc1ccc(C2=C(C(=O)Nc3ccc(N4CCN(Cc5cccc(C#N)c5)CC4)cc3)CCCC2)cc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FAAH O00519 1/20 0.49
TP53 P04637 2/20 0.48
SLC2A1 P11166 1/20 0.48
MAPT P10636 7/20 0.47
LMNA P02545 3/20 0.47
SMN1; SMN2 Q16637 2/20 0.47
RORC P51449 1/20 0.46
PRKAA2 P54646 1/20 0.45
TSHR P16473 2/20 0.45
MAPK1 P28482 1/20 0.45
MCHR1 Q99705 1/20 0.43
HTT P42858 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
ACKR3 P25106 1/20 0.42
GPR6 P46095 1/20 0.42
KDM4E B2RXH2 2/20 0.42
ALDH1A1 P00352 2/20 0.42
AURKA O14965 1/20 0.42
ITK Q08881 1/20 0.42
RAB9A P51151 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6499147 0.91 MAPT (0.46) FAAHMAPTLMNASMN1; SMN2PRKAA2
SCHEMBL6488692 0.90 SLC2A1 (0.52) FAAHSLC2A1MAPTLMNASMN1; SMN2
SCHEMBL6489230 0.88 PRKAA2 (0.47) FAAHTP53SLC2A1MAPTRORC
SCHEMBL6498772 0.87 MAPT (0.58) FAAHTP53MAPTLMNASMN1; SMN2
SCHEMBL6504210 0.83 KMT2A (0.45) SLC2A1MAPTLMNASMN1; SMN2TSHR
SCHEMBL6490947 0.82 HIF1A (0.51) FAAHMAPTLMNASMN1; SMN2L3MBTL1
SCHEMBL6490282 0.79 AR (0.45) SLC2A1
SCHEMBL6499900 0.79 DRD2 (0.46) TP53MAPTLMNASMN1; SMN2TSHR
SCHEMBL6487861 0.79 SLC2A1 (0.49) FAAHSLC2A1MAPTSMN1; SMN2RORC
SCHEMBL6492454 0.78 MAPT (0.41) TP53MAPTLMNASMN1; SMN2TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050038035-A1 Heterocyclic amide compounds as apolipoprotein b inhibitors DAISO CO., LTD. (JP) 2005-02-17 US disclosed
EP-1472226-A1 HETEROCYCLIC AMIDE COMPOUNDS AS APOLIPOPROTEIN B INHIBITORS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-11-03 EP disclosed
WO-2003045921-A1 HETEROCYCLIC AMIDE COMPOUNDS AS APOLIPOPROTEIN B INHIBITORS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2003-06-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050038035-A1 Heterocyclic amide compounds as apolipoprotein b inhibitors APOB, APOL1, CTRB2 FAAH 405/4885TP53 3031/4885SLC2A1 1022/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.